About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
MoreMenu
CloseWhite
About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
News
Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Asgard Therapeutics Strengthens Scientific Advisory Board with Two Appointments
Asgard Therapeutics announces publication on direct reprogramming of cancer cells to force antigen presentation, in collaboration with Lund University
Eurostars-funded REPRINT consortium reaches milestones with evidence of complete tumor regression induced by dendritic cell reprogramming
Asgard Therapeutic’s scientific founders publish the pioneering paper describing dendritic cell direct reprogramming in mouse cells.
Posted 25 December, 2018